- Home
- LFT vs ADAG Comparison
LFT vs ADAG Comparison
Compare LFT & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFT
- ADAG
- Stock Information
- Founded
- LFT 2012
- ADAG 2011
- Country
- LFT United States
- ADAG China
- Employees
- LFT N/A
- ADAG N/A
- Industry
- LFT Real Estate Investment Trusts
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- LFT Real Estate
- ADAG Health Care
- Exchange
- LFT Nasdaq
- ADAG Nasdaq
- Market Cap
- LFT 82.2M
- ADAG 84.8M
- IPO Year
- LFT N/A
- ADAG 2021
- Fundamental
- Price
- LFT $1.62
- ADAG $2.09
- Analyst Decision
- LFT Hold
- ADAG Strong Buy
- Analyst Count
- LFT 1
- ADAG 4
- Target Price
- LFT N/A
- ADAG $8.00
- AVG Volume (30 Days)
- LFT 224.7K
- ADAG 103.9K
- Earning Date
- LFT 11-12-2025
- ADAG 08-12-2025
- Dividend Yield
- LFT 10.06%
- ADAG N/A
- EPS Growth
- LFT N/A
- ADAG N/A
- EPS
- LFT 0.09
- ADAG N/A
- Revenue
- LFT $21,708,246.00
- ADAG $103,204.00
- Revenue This Year
- LFT $124.75
- ADAG $7,411.34
- Revenue Next Year
- LFT N/A
- ADAG $28.29
- P/E Ratio
- LFT $16.89
- ADAG N/A
- Revenue Growth
- LFT N/A
- ADAG N/A
- 52 Week Low
- LFT $1.42
- ADAG $1.30
- 52 Week High
- LFT $2.84
- ADAG $3.16
- Technical
- Relative Strength Index (RSI)
- LFT 52.09
- ADAG 60.91
- Support Level
- LFT $1.42
- ADAG $1.78
- Resistance Level
- LFT $1.56
- ADAG $1.99
- Average True Range (ATR)
- LFT 0.06
- ADAG 0.20
- MACD
- LFT 0.03
- ADAG 0.04
- Stochastic Oscillator
- LFT 95.00
- ADAG 92.42
About LFT Lument Finance Trust Inc.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.